Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ted Ohashi-Bunka interview Pg. 7
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_fb7fedcba9454f1ab1fd34375f292bc0.pdf
Cannadips international expansion news https://ir.lexariabioscience.com/news-events/press-releases/detail/182/cannadips-is-expanding-intern
Lexaria, a global innovator in drug delivery platforms is pleased to announce that its DehydraTECH licensee Boldt Runners Corporation, owners of the Cannadips Brand, has expanded manufacturing agreements to include Europe, Japan, and South Africa.
For anyone interested in what's going on with Juul right now, there is an excellent one hour podcast on Twitterspace about it. It is an hour and three minutes with Amanda Wheeler and others. It and other podcasts on related subjects are available on CASAA' youtube page at https://www.youtube.com/c/CASAA/featured.
General market selloff ahead of the long weekend.
Bigger volume and down, down. Somethings wrong here.
Interesting to see some increasing share volume coming in this morning with a long weekend ahead.
No, but it will help KAVL in a big way!!!! Small offering above the trading price soon and then off to double digits
If you shorted the stock at $2 you'd be hurting right now too! Seems just as pointless to mention...just saying.
Premier very likely has huge plans for DehydraTECH if Lexaria expects such huge royalty revenues. I didn't say what I thought was reasonable or not. Don't shoot the messenger!
Totally agree my comment was sarcasm
Week before split stock was over $8 equivalent, the day before the split was announced it was $7.55...we are nowhere near "pre-split levels." Year before the split was at $14.
In fact, if you'd bought the day after the split caused the stock to crash briefly, you'd still be down.
The stock is only above all time lows that it hit in May
That's a projection based on projected sales for a product that doesn't exist yet.
The actual deal for exclusivity would yield $5mm total IF they get paid it.
You made it seem like it's reasonable to expect $5mm per year, which it's not at all.
Abundance- thank you eom
Bevnology is the Research and Development arm of the larger company Intercontinental Beverage Capital with as near as I can see 25 employees and $5M rev.
https://www.zoominfo.com/c/intercontinental-beverage-capital-inc/358937538
https://inbevcapital.com/about/
https://ir.lexariabioscience.com/news-events/press-releases/detail/181/lexaria-signs-manufacturing-and-license-agreements-with
It appears IBC has offices and connections globally that help Food and Beverage companies with all the issues that pertain to successfully launching new products. Seems to be a useful partner to have IMO. https://inbevcapital.com/contact/
Bevnology mentioned by Ted O - 5 employees --founded 2012-- revenues of $952 - did I miss something great here? -- I hope
Ted Ohashi
"One bit of news is that the U.S. Food and Drug Administration (FDA) has banned the sale of Juul ecigarettes from the United States market. Apart from the fact that Juul did not provide the data needed to convince the FDA to allow marketing to continue. There may have been a little bit of vindictiveness in the FDA’s action as it also mentioned that Juul had a disproportionate impact on youth vaping. Altria also has an interest in Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) nicotine. Although having their $12.8 billion investment in Juul effectively incinerated it may change Altria’s direction toward ingested delivery of nicotine.
"Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) announced signing two agreements with
Atlanta-based BevNology LLC ("BevNology").
1. The first agreement is a manufacturing operating agreement that expands production capabilities for LEXX’s own growing list of business-to-business (B2B) clientele interested in
purchasing DehydraTECH-powered active ingredients for consumer packaged-goods
brands. A new, state-of-the-art processing facility custom-built by BevNology is operational
that increases and broadens production capacity and is currently serving Lexaria's corporate clients. Lexaria has moved and installed all required commercial DehydraTECH manufacturing equipment into BevNology's new facility as it prepares for future growth in its B2B ingredient processing business.
2. The second agreement is a commercial license empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including cannabidiol (CBD) under BevNology and partnered brands. For powdered DehydraTECH formulations this agreement is non-exclusive. For liquid
ehydraTECH formulations, where BevNology has
highly specialized skills and capabilities, the license is non-exclusive in most areas of the
world but includes limited exclusivity rights in the U.S. only that require certain minimum
fee payments in order to maintain those rights. Lexaria will receive royalties from BevNology as a result of their utilization of this license. The only countries specifically excluded
under this license are Japan, the Republic of Korea, and the People's Republic of China.
"These are two separate agreements. The first is a new agreement to have BevNology manufacture the products that LEXX sells to commercial customers in facilities that LEXX CEO describes as “class leading.” The second is a more conventional commercial contract that licenses BevNology to use LEXX’s technology in return for royalties on sales.
Conclusion: I recently described the series of recent commercial agreements announced by Lexaria
Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) as adding grains of sand on the scales measuring LEXX’s valuation in the market. You never know which deal causes the scale to turn sharply in LEXX’s favour. It is clear, however, that shift is taking place."
Here is some news that impacted LEXX just this month.
• June 21, 2022: BevNology commercial and manufacturing contract.
• June 17, 2022: I reported between June 6 - 17, 2022 the number of LEXX reported short sales divided by the total volume of off exchange trading declined sharply from a Short Volume Ratio of 43.67 to 8.18. The Short Volume Ratio is the Short Volume divided by Total off exchange Volume reported.
• June 8, 2022: AnodGen Bioceuticals commercial sales agreement
• June 6, 2022: Pre-IND meeting request letter with U.S. Food and Drug Administration
• June 3, 2022: Premier Wellness Science sales agreement including Premier’s worldwide independent assessment of DehydraTECH™ as their technology of choice
• June 2, 2022: Valcon Medical in the European Market
13
Conclusion: It appears to me that the recent acceleration in LEXX’s B2B commercial sales have not
been lost on investors. At the same time, the even more explosive growth potential comes from the steps taken on the hypertension front with the U.S. FDA.
What investors see is the increasing credibility of LEXX’s business model to generate sufficient B2B royalty revenue to sustain operations. It should not be forgotten that royalty revenue is the equivalent of gross profit for other operators because there is no ‘cost of goods sold’ associated.
Finally, investors should remember that the business plan always contemplated separating the different
applications of the technology. This means the DehydraTECH™ application in CBD is separate from its application in nicotine that is separate from antiviral drugs that is separate from PDE5 inhibitors and more. The “blue sky” implication is with hypertension it is possible that LEXX could replicate the GW
Pharma success or see it completed by a partner and it is within the realm of possibility that it could be repeated many times over. All of this is speculative but it is, at least, within the realm of possibilities.
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_c36ce2a24ea94e54bae68b89f35a09f2.pdf
To clarify...A deal with Altria would help LEXX!
How would a deal with LEXX help Juul?
WSJ reports FDA to order Juul e cigarettes off US market. https://www.wsj.com/articles/fda-to-order-juul-e-cigarettes-off-u-s-market-11655904689
Maybe this could help LEXX get a deal with them.
Jump back to pre split levels,wonderfull
OK, right. That explains it. Thanks abundance.
The deal with Premier gives them right of first refusal for these areas.
"In order to encourage the expansion of DehydraTECH-enhanced Products within Asia, Premier has also been provided with a right of first refusal until May 20, 2025, to any license for the Technology in the nations of the People’s Republic of China and the Republic of Korea".
https://ir.lexariabioscience.com/sec-filings/all-sec-filings##document-1741-0001640334-22-001179-2
"The only countries specifically excluded under this license are Japan, the Republic of Korea, and the People's Republic of China."
Are China and Korea next?
We need Altria to take us to the altar. LOL
Yes, holding my breathe that we may finally be at the alter. A $10/$20/$30 jump would not surprise me
It reaffirms my faith in the technology when major corporations like IBC and Premier Wellness sign deals wit lexaria. You know that they have done extensive due diligence and have selected the best.
We were chatting about "facts" not too long ago...
There's another "fact".
I don't think any other company can say this.
"Lexaria's DehydraTECH TM -CBD nanoemulsification formulation and processing techniques exhibited exceptional stability one year after production with less than 1% variability in CBD potency in fractions sampled from the top, middle and bottom of the beverage formulation without physical mixing or agitation; and, CBD content was verified at 93.4% of target potency and also evidenced excellent microbial purity after 12 months."
Another deal, 26,000 shares traded. What does it take to get multi million share up days on this puppy??
Premier Wellness Science
Produce the best products
Behind the creation of a single brand, we are developing products based on scientific quantitative data in collaboration with
medical and pharmaceutical researchers, research institutes, and biotechnology companies . In today's world of product turmoil, obtaining solid evidence is the key to becoming a leading brand in that area. “We create the best products.” We are forming and working on a complex global partnership to achieve this simple result .
To create a global brand
Our brands are sold after undergoing rigorous quality checks. We believe that
products with solid efficacy, emotional visual design,
communication with customers, and all of these activities
will foster a brand image and form a world-leading and outstanding brand identity.
It says this right in the press release: "If Premier achieves even their worst-case projected penetration into the Japanese non-pharmaceutical CBD market, then based on their projections Lexaria could expect to receive annual payments of over $5 million by the fifth year of the contract."
It's not in the negotiated part!
Also, the huge multi million dollar revenues of the parent company could be very meaningful going forward. Better than making deals with broke companies with no revenue!
Smoke and Mirrors. Deals are with friends and friends of friends, with companies with very little business, 2 employees and a garage for an office. Still no meat on these bones, $2.22 with this.....supposedly incredible flow of announcements.
NOT $5mm per year
"In order to retain ongoing exclusivity, the negotiated minimum quarterly payments ("Payments") to Lexaria begin September 1, 2022 and, during the first five years of the Agreement, amount to US$4,527,500."
It DOES NOT say this amount PER YEAR...if it was per year, it would be explicit. That's the total. Also, that is only to maintain EXCLUSIVITY. They do not need to maintain exclusivity at the moment as Lexaria has no other Japan deals ad hasn't mentioned any. So, it's feasable that they never make any of these payments unless a major competitor wants to use the tech.
Also, who cares what this company's PARENT sales are. This is a red herring to make people think this deal has large potential. At the moment, this company's revenue do not come from products that LEXX's tech will help, so they are creating new products (maybe).
The article doesn't even mention what products might be created.
This partnership at the moment, is fairly meaningless and basically says nothing more than "Japanese cosmetics company might start using our technology, and if they do, we will get royalty payments, but we aren't saying what they are. BUT, they would have to pay to keep us from licensing our tech to other Japanse companies, but we haven't started doing that yet either."
Ted Ohashi Let's Toke Business Pg. 11
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_49796dbd6f0a4b31b20ff1c009fbb7dc.pdf
The deal with Japan's Premier Wellness is expected to pay Lexaria at least $5M per year by the fifth year of the contract. A bit more than a shell type!
"Premier's Parent had revenues of approximately US$187,000,000 in the first three quarters of fiscal 2021 with year-over-year revenue growth of 63.1% and strong profit margins. Parent sells over 45 product SKU's across four brands, and these products are sold in more than 16,000 retail stores as well as directly through mail/web order to over 2.6 million proprietary members. The overall Japanese cosmetics and personal products markets are estimated to be more than US$35 billion in annual sales". https://ir.lexariabioscience.com/news-events/press-releases/detail/178/lexaria-grants-exclusive-license-to-premier-wellness
But agreed that "big boy" contracts are welcome!
Very fair point Agent. Need a big boy to sign up, not all these shell type looking deals with no names.
IMO the implication was passive aggressive. Why beat around the bush with this..."I think such and such". Posters should say what they mean instead of letting it be open to interpretation.
I believe the implication was simply that Lexaria can't seem to get any coverage (i.e., interest) aside from the coverage it pays for; which, IMHO, is a fair point.
Lexaria has overhead costs...OMG. What kind of business are they running?!!! lol
Well... I'm sure we can all agree that there's a difference between you figuring your story ought to be told - and paying someone to tell it - and someone else figuring your story ought to be told - and paying someone to tell it.
True, stock analysts don't work for free.
I think Lexaria paid Zacks to cover the stock, though.
It's a licensing deal. That's Lexaria's business model. Nothing wrong with royalties. So far we have 12 companies now licensed to us. Imagine the money rolling in when we have 100 or 500!
So in this latest deal with AnodGen no mention of upfront money just the royalties. Did I miss that?
All these deals one after another...it's just terrible lol
Followers
|
219
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
34646
|
Created
|
10/02/07
|
Type
|
Free
|
Moderators |
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through measurement of the increase in salivary nitric oxide as a directly proportional surrogate biomarker, with onset of action in as little as 15-30 minutes. In all cases, the maximum increased level of salivary nitric oxide remained evident at the 60-minute end period of this particular test. Further testing is required to determine the full duration of elevated nitric oxide levels.
Thereafter, a blinded human focus study was conducted to evaluate the performance of THC-infused chocolates formulated using Lexaria’s DehydraTECH™ technology. This study compared the performance of the THC-infused chocolates powered by Lexaria’s technology to concentration matched THC-infused chocolates formulated using a commercial dextrin absorption enhancer. The subjects (n=12) that participated in this study indicated a clear preference on taste and overall effectiveness with the chocolates formulated using Lexaria’s technology, and onset of effectiveness was again observed very quickly, in as little as 15-20 minutes.
Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Contact us today to speak about your licensing needs at ablanchard@lexariabioscience.com
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of chemicals or intimidating, complex ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, gluten-free, and dairy free.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption
Increases bio-absorption by 2 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects. More recent testing in animals even demonstrated an ability to cross the blood-brain-barrier to a degree previously thought not possible.
Interview with CEO Chris Bunka
https://youtu.be/9bRSWYKIEL8
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
Kelowna, British Columbia – June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.
BACKGROUND
On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.
In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).
Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.
TEST RESULTS
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.
On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).
Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.
CONCLUSION
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |